Goodwin Procter advised SonoThera, Inc. on the deal. SonoThera, Inc. announced its $60.75 million Series A financing round to support the continued development of SonoThera’s ultrasound-guided, nonviral,...
SonoThera’s $60.75 Million Series A Funding
FogPharma’s $178 Million Series D Financing
Goodwin Procter advised FogPharma® on the deal. FogPharma® announced its $178 Million Series D financing. FogPharma is a biopharmaceutical company pioneering a new class of precision...
Novo Nordisk’s $1.1 Billion Acquisition of Forma Therapeutics
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
Royalty Pharma’s Acquisition of Royalty Interest in TRELEGY ELLIPTA
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
Royalty Pharma’s Acquisition of Theravance Respiratory Company
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
Proparco’s $140 Million Financing of Banco BTG Pactual S.A.
Becker, Glynn, Muffly, Chassin & Hosinski LLP advised Société de Promotion et de Participation pour la Coopération Economique (Proparco) of France on the deal. Société de...